Clinical relevance of monitoring serum levels of adalimumab in patients with rheumatoid arthritis in daily practice

Clinical and Experimental Rheumatology

Volumn 32, Issue 6, 2014, Pages 942-948

  Rosas, José ^a   Tello, Francisca Llinares ^a   de la Torre, Immaculada ^b   Santos Ramírez, Carlos ^c   Senabre Gallego, José Miguel ^a   Valor, Lara ^b   Barber Vallés, Xavier ^d   Hernández Flórez, Diana ^b   Santos Soler, Gregorio ^a   Salas Heredia, Esteban ^a   Carreño, Luis ^b   de Salazar, José Rosas Gómez ^a   Heredia, Esteban Salas ^a   Pérez, Catalina Cano ^a   Bas, Ana Pons ^a   Betoret, Marisa Lorente ^a   García, Juan Molina ^a   Ramírez, Carlos Santos ^c   Castro, Rafaela Ortega ^c   Barrioluego, Mabel Sánchez ^e   García Carrasco, Mario ^f,g   more..

^a HOSPITAL MARINA BAIXA   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^c Hospital Marina Salud de Denia   (Spain)

^d MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

^e UNIVERSITAT POLITÈCNICA DE VALÈNCIA   (Spain)

^f INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^g BENEMÉRITA UNIVERSIDAD AUTÓNOMA DE PUEBLA   (Mexico)

Author keywords

Adalimumab; Anti TNF therapy; Disease activity; Rheumatoid arthritis; Treatment outcome

Indexed keywords

ADALIMUMAB; DRUG ANTIBODY; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; ANTIRHEUMATIC AGENT; BIOLOGICAL MARKER; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; BLOOD SAMPLING; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; DAS28; DISEASE ACTIVITY; DRUG BLOOD LEVEL; DRUG RESPONSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; REMISSION; RHEUMATOID ARTHRITIS; SIMPLIFIED DISEASE ACTIVITY INDEX; TREATMENT DURATION; AGED; AREA UNDER THE CURVE; ARTHRITIS, RHEUMATOID; BLOOD; CLINICAL TRIAL; DRUG MONITORING; IMMUNOLOGY; MIDDLE AGED; MULTICENTER STUDY; PREDICTIVE VALUE; SPAIN; TIME; TREATMENT OUTCOME;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; AREA UNDER CURVE; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; CROSS-SECTIONAL STUDIES; DRUG MONITORING; FEMALE; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; ROC CURVE; SPAIN; TIME FACTORS; TREATMENT OUTCOME;

EID: 84925283113     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. VINCENT FB, MORAND EF, MURPHY K, MacKAY F, MARIETTE X, MARCELLI C: Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective. Ann Rheum Dis 2013; 72: 165-78.
2. BENDTZEN K: Personalized medicine: theranostics (therapeutics diagnostics) essential for rational use of tumor necrosis factor-alpha antagonists. Discov Med 2013; 15: 201-11.
3. PASCUAL-SALCEDO D, PLASENCIA C, RAMIRO S et al.: Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis. Rheumatology (Oxford) 2011; 50: 1445-52.
4. WOLBINK GJ, VIS M, LEMS W et al.: Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum 2006; 54: 711-5.
5. BARTELDS GM, KRIECKAERT CL, NURMOHAMED MT et al.: Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 2011; 305: 1460-8.
6. DORE RK, MATHEWS S, SCHECHTMAN J et al.: The immunogenicity, safety, and efficacy of etanercept liquid administered once weekly in patients with rheumatoid arthritis. Clin Exp Rheumatol 2007; 25: 40-6.
7. BARTELDS GM, WIJBRANDTS CA, NURMOHAMED MT et al.: Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 2007; 66: 921-6.
8. POUW MF, KRIECKAERT CL, NURMOHAMED MT et al.: Key findings towards optimising adalimumab treatment: the concentration-effect curve. Ann Rheum Dis 2013 Dec 10 [Epub ahead of print].
9. JAMNITSKI A, KRIECKAERT CL, NURMOHAMED MT et al.: Patients non-responding to etanercept obtain lower etanercept concentrations compared with responding patients. Ann Rheum Dis 2012; 71: 88-91.
10. ROSAS J, LLINARES-TELLO F, SENABRE JM et al.: Evaluation of anti-TNF levels and anti. TNF antibodies in rheumatic diseases treated with infliximab and adalimumab; results from a local registry. [Abstract]. Ann Rheum Dis 2011; 63 (Suppl. 10): S2211.
11. ROSAS J, LLINARES-TELLO F, de la TORRE I et al.: Clinical usefulness of serum level of adalimumab, in patients with rheumatoid arthritis. [Abstract]. Ann Rheum Dis 2013; 72(Suppl. 3): 333.
12. KRIECKAERT CL, NAIR SC, NURMOHAMED MT et al.: Personalised treatment using serum drug levels of adalimumab in patients with rheumatoid arthritis: an evaluation of costs and effects. Ann Rheum Dis 2013 Nov 21 [Epub ahead of print].
13. BREEDVELD FC, WEISMAN MH, KAVANAUGH AF et al.: The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006; 54: 26-37.
14. KLARESKOG L, van der HEIJDE D, De JAGER JP et al.: Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004; 363: 675-81.
15. KEYSTONE E, HEIJDE DV, MASON D Jr et al.: Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebocontrolled, parallel-group study. Arthritis Rheum 2008; 58: 3319-20.
16. KRIECKAERT CL, NURMOHAMED MT, WOLBINK GJ: Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner. Ann Rheum Dis 2012; 71: 1914-5.
17. ARNETT FC, EDWORTHY SM, BLOCH DA et al.: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
18. PREVOO ML, van't HOF MA, KUPER HH, van LEEUWEN MA, van de PUTTE LB, van RIEL PL: Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44-8.
19. SMOLEN JS, BREEDVELD FC, SCHIFF MH et al.: A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford) 2003; 42: 244-57.
20. LLINARES-TELLO F, ROSAS GÓMEZ De SALAZAR J, SENABRE GALLEGO JM et al.: Analytical and clinical evaluation of a new immunoassay for therapeutic drug monitoring of infliximab and adalimumab. Clin Chem Lab Med 2012; 50: 1845-7.
21. LLINARES-TELLO F, ROSAS J, De La TORRE I, VALOR L, BARBER X, SENABRE JM: Comparative study of both versions of an immunoassay commercialized for therapeutic drug monitoring of adalimumab in rheumatoid arthritis. Rheumatol Clin 2014; 10: 105-8.
22. RUIZ-ARGÜELLO B, RUIZ DEL AGUA A, TORRES N, MONASTERIO A, MARTÍNEZ A, NAGORE D: Comparison study of two commercially available methods for the determination of infliximab, adalimumab, etanercept and anti-drug antibody levels. Clin Chem Lab Med 2013; 51: e287-9.
23. RISPENS T, van der KLEIJ D: Reply to RUIZARGÜELLO et al.: Comparison study of two commercially available methods for the determination of infliximab, adalimumab, etanercept and anti-drug antibody levels. Clin Chem Lab Med 2013; 51: e291-2.
24. PATTON A, MULLENIX MC, SWANSON SJ, KOREN E: An acid dissociation bridging ELISA for detection of antibodies directed against therapeutic proteins in the presence of antigen. J Immunol Methods 2005; 304: 189-95.
25. LLINARES-TELLO F, ROSAS-GÓMEZ De SALAZAR J, SENABRE-GALLEGO JM et al.: Practical application of acid dissociation in monitoring patients treated with adalimumab. Rheumatol Int 2014 May 10 [Epub ahead of print].
26. R DEVEL OPMENT CORE TEA M (2013): A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. http://www.R-project. org/.
27. van KUIJK AW, De GROOT M, STAPEL SO, DIJKMANS BA, WOLBINK GJ, TAK PP: Relationship between the clinical response to adalimumab treatment and serum levels of adalimumab and anti-adalimumab antibodies in patients with psoriatic arthritis. Ann Rheum Dis 2010; 69: 624-5.
28. KRIECKAERT C, RISPENS T, WOLBINK G: Immunogenicity of biological therapeutics: from assay to patient. Curr Opin Rheumatol 2012; 24: 306-11.
29. De STEFANO R, FRATI E, NARGI et al.: Comparison of combination therapies in the treatment of rheumatoid arthritis: leflunomide-anti-TNF-alpha versus methotrexate-anti-TNFalpha. Clin Rheumatol 2010; 29: 517-24.
30. BENUCCI M, SAVIOLA G, BAIARDI P, MANFREDI M, SARZI-PUTTINI P, ATZENI F: Efficacy and safety of leflunomide or methotrexate plus subcutaneous tumour necrosis factoralpha blocking agents in rheumatoid arthritis. Int J Imunnopathol Pharmacol 2011; 24: 269-74.
31. JAMNITSKI A, BARTELDS GM, NURMOHAMED MT et al.: The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept. Ann Rheum Dis 2011; 70: 284-8.
32. WOLBINK GJ, AARDEN LA, DIJKMANS BA: Dealing with immunogenicity of biologicals: assessment and clinical relevance. Curr Opin Rheumatol 2009; 21: 211-5.
33. GARCÊS S, ANTUNES M, BENITO-GARCIA E, da SILVA JC, AARDEN L, DEMENGEOT J: A preliminary algorithm introducing immunogenicity assessment in the management of patients with RA receiving tumour necrosis factor inhibitor therapies. Ann Rheum Dis 2014; 73: 1138-43.